| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
InflaRx N.V.$1.93
0 (0%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
188.68 M
EPS
-
P/E Ratio
-
Value Trade
2.94 M
9.66 %
Week
51.74 %
1 Month
190.35 %
3 Month
119.33 %
6 Month
-11.82 %
5 Year
-82.82 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
546.37 K
52 Week Range
0.71 - 2.95
% held by Insiders
12.79 %
% held by Institutions
18.04 %
Enterprise Value
143.77 M
Total Shares
67.74 M
Short %
10.8 %
Float Shares
63.40 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D33
Pipeline Score $18M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 43%
Micro Cap (rank 517 of 905)
Percentile RankInflaRx N.V. faces pipeline headwinds (33/100), with $914M risk-adjusted pipeline value, led by IFX-1 + BSC in Severe COVID-19 Pneumonia (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IFX-1 Monoclonal antibody | Hidradenitis Suppurativa | Phase 2 | NCT03001622 | 26% | $640M | COMPLETED | 12 | - | - | Jul 1, 2017 | - | Sep 19, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vilobelimab | acute respiratory distress syndrome (ARDS),pyoderma gangrenosum (PG) | Phase 3 | 2025-08-08 | |||
vilobelimab | acute respiratory distress syndrome (ARDS),pyoderma gangrenosum (PG) | Phase 3 | 2025-08-08 | |||
vilobelimab | acute respiratory distress syndrome (ARDS),pyoderma gangrenosum (PG) | Phase 3 | 2025-08-08 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IFRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IFRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IFRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IFRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IFRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IFRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IFRXInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has completed an underwritten offering of 75 million ordinary shares at $2.00 each, raising $150 million. The proceeds will be utilized to further develop its pipeline and for general corporate needs. The offering saw participation from various investors, including prominent healthcare funds. Guggenheim Securities led the offering.
Read more →IFRXInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx N.V. has announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 each, aiming to raise $150 million. The proceeds will be utilized for advancing pipeline activities and general corporate purposes. The offering is set to close on May 7, 2026, pending customary conditions.
Read more →IFRXInflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx N.V. is advancing izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis and other renal diseases. The company plans to conduct Phase 2 studies and aims to establish proof of concept in additional life-threatening kidney disorders. A Capital Markets Day is scheduled for summer 2026 to discuss izicopan's potential. InflaRx has sufficient funding to support its development programs through 2029.
Read more →IFRXInflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx announced favorable pre-clinical data for izicopan, showing low reactive metabolite formation in human liver microsomes. This suggests a lower bioactivation-related safety risk compared to avacopan, a marketed C5aR1 inhibitor. The results support izicopan's potential for improved efficacy and safety in treating inflammatory diseases. The company aims to further validate these findings in clinical studies.
Read more →IFRXInflaRx to Report First Quarter 2026 Results on May 7, 2026
InflaRx N.V. will release its financial results for Q1 2026 on May 7, 2026, prior to market opening. The company is known for its innovative anti-inflammatory therapeutics targeting the complement system, particularly through its lead program izicopan. No conference call is scheduled for this announcement.
Read more →IFRXInflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx N.V. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company achieved this by maintaining a closing bid price of $1.00 or greater for 10 consecutive business days. This compliance is crucial for the company's continued listing on Nasdaq and reflects positively on its market performance.
Read more →IFRXThis is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch
InflaRx N.V. has enacted a deed of amendment to its articles of association, as decided during a general meeting of shareholders in Amsterdam. The amendment involves particular changes to the company's structure and share capital, with a specific focus on adjusting nominal values. The changes are set to take effect upon the issued share capital reaching a stipulated amount. This amendment follows a previous adjustment made in April 2025.
Read more →IFRXInflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx N.V. has reported new in vitro data indicating that izicopan, an oral C5a receptor inhibitor, does not cause time-dependent inhibition of CYP3A4, which is crucial for assessing drug-drug interactions. This finding supports izicopan's potential as a best-in-class treatment for inflammatory diseases. The drug has demonstrated favorable pharmacokinetic and pharmacodynamic profiles in clinical studies.
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2026 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has issued a convening notice for its 2026 annual general meeting scheduled for April 23, 2026, in Amsterdam. The agenda includes the adoption of the annual accounts for 2025, reappointments of key executives, and auditor nomination. The company has also reiterated its policy of not paying dividends in the foreseeable future, focusing instead on retaining funds for business development. Shareholders must follow specific protocols to attend or vote at the AGM.
Read more →IFRXInflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx N.V. announced its participation in the Raymond James 2026 Biotech Innovation Symposium, scheduled for April 14, 2026, in New York. The company will engage in one-on-one investor meetings during the event. InflaRx focuses on anti-inflammatory therapeutics, with its lead program izicopan showing promise in clinical studies for inflammatory diseases.
Read more →IFRXInflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx presented promising Phase 3 data for vilobelimab in treating pyoderma gangrenosum at the 2026 AAD Annual Meeting. The study showed higher rates of complete remission and ulcer closure compared to placebo, alongside a favorable safety profile. However, the trial was halted early due to futility, raising concerns about its efficacy. The company is exploring further development options for vilobelimab.
Read more →IFRXInflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and sa
InflaRx N.V. reported strong financial results for 2025 and highlighted key achievements in its therapeutic pipeline, particularly focusing on izicopan for hidradenitis suppurativa and chronic spontaneous urticaria. The CEO emphasized the promising Phase 2a clinical data, which showed rapid and meaningful treatment effects. The company plans to advance izicopan towards Phase 2b trials and is actively engaging with the FDA for further development. Additional focus on other indications and a clear path forward is expected to position InflaRx favorably in the market.
Read more →IFRXInflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V. has announced a late-breaking oral presentation for their Phase 3 results of vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting. The presentation, led by Dr. Benjamin Kaffenberger, will take place on March 28, 2026. InflaRx aims to highlight the significance of their findings regarding C5a/C5aR inhibition in the treatment of inflammatory diseases.
Read more →IFRXInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Jena, Germany
InflaRx N.V. has received a written notice from Nasdaq indicating that its stock price has fallen below the minimum bid price requirement of $1.00 per share for the past 30 business days. The company has been given an initial period of 180 days to regain compliance, up until September 7, 2026. If compliance is not achieved, InflaRx may consider transferring to the Nasdaq Capital Market for an additional compliance period, though approval for this is uncertain. The notice does not immediately affect the company's stock listing or trading.
Read more →IFRXInflaRx to Report Full Year 2025 Results on March 19, 2026
InflaRx N.V. will release its financial and operational results for Q4 and full year 2025 on March 19, 2026. The company is known for its innovative anti-inflammatory therapeutics, particularly its lead program izicopan, which has shown promise in clinical trials. No conference call is scheduled for the results announcement.
Read more →IFRXInflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
InflaRx N.V. announced its participation in the Leerink Partners Global Healthcare Conference, scheduled for March 8-11, 2026, in Miami, FL. The company will host a fireside chat on March 9 at 9:20 AM ET and conduct one-on-one investor meetings. InflaRx specializes in anti-inflammatory therapeutics, with its lead program izicopan showing promise in clinical studies.
Read more →IFRXInflaRx Announces Participation in February Investor Conferences
InflaRx N.V. has announced its participation in several investor conferences scheduled for February 2026. The company will present at the Guggenheim Securities Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. InflaRx is focused on developing innovative anti-inflammatory therapies, including izicopan and vilobelimab.
Read more →IFRXInflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readine
InflaRx N.V. has announced a strategic focus on enhancing capital efficiency and prioritizing the development of izicopan for hidradenitis suppurativa and other inflammatory indications. The company is undertaking significant cost-cutting measures, including a 30% workforce reduction and substantial cuts in spending for its Gohibic program. This realignment aims to extend cash runway and concentrate resources on its leading pipeline asset, which the company believes has best-in-class potential. InflaRx is also engaging with the FDA for Phase 2b study planning and anticipates conducting proof-of-concept studies in multiple I&I indications.
Read more →IFRXInflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
InflaRx N.V. has provided an update on the Phase 3 study of vilobelimab for pyoderma gangrenosum, which was halted early due to futility. Despite this, data analyses revealed potential efficacy signals, particularly in ulcer volume reduction. The company plans to meet with the FDA to discuss future development pathways, possibly in collaboration with a partner.
Read more →IFRXInflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
InflaRx N.V. announced that the World Health Organization has granted the international nonproprietary name 'izicopan' for its C5aR inhibitor, previously known as INF904. This name will be published in the recommended list of INNs. The company reports promising clinical data for izicopan in treating hidradenitis suppurativa and chronic spontaneous urticaria, highlighting its potential as a leading oral treatment.
Read more →IFRXInflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
InflaRx N.V. announced positive topline data from its Phase 2a study of INF904 for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study demonstrated significant efficacy and a strong safety profile across multiple dosing regimens. The company plans to advance INF904 into Phase 2b trials, targeting further development in both indications.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
InflaRx N.V. has released its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025. The company reported a significant net loss of €34,991,387, alongside a decrease in equity and a deterioration in cash reserves. The financial results indicate a consistent trend of operational and comprehensive losses compared to previous periods. Additionally, the financial asset figures showed a decrease from past totals, highlighting the challenges facing the company.
Read more →IFRXInflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
InflaRx N.V. is set to announce topline data from its Phase 2a clinical trial of INF904, an oral C5aR inhibitor, targeting hidradenitis suppurativa and chronic spontaneous urticaria on November 10, 2025. Along with this announcement, the company plans to release its third quarter 2025 financial results, which will be presented in a webcast including insights from key opinion leaders. InflaRx is advancing its portfolio of anti-inflammatory therapeutics, having previously developed vilobelimab, a first-in-class anti-C5a monoclonal antibody.
Read more →IFRXInflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
InflaRx N.V. announced its participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, scheduled for November 10-12, 2025, in Boston. The company will host a fireside chat on November 11 and conduct one-on-one investor meetings. InflaRx focuses on developing anti-inflammatory therapeutics, including vilobelimab, a first-in-class monoclonal antibody.
Read more →IFRXInflaRx Announces Participation in September Investor Conferences
InflaRx N.V. will participate in two investor conferences in September 2025, including the Cantor Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. The company will host fireside chats and one-on-one meetings to discuss its anti-inflammatory therapeutics, particularly its anti-C5a monoclonal antibody, vilobelimab.
Read more →IFRXInflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
InflaRx N.V. reported its financial results for Q2 2025, highlighting the development of INF904, an oral C5aR inhibitor. The company anticipates significant data from its Phase 2a trial in chronic spontaneous urticaria and hidradenitis suppurativa by late September to early November. Despite a decrease in revenue from vilobelimab, InflaRx maintains a strong financial position with a cash runway into 2027.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its who
InflaRx N.V. has released its unaudited condensed consolidated financial statements for the six months ended June 30, 2025. The results show a significant loss of €22.73 million, contributing to a total comprehensive loss of approximately €22.99 million during the same period. The company's operating results indicate a decline in gross profit, juxtaposed with rising operational costs, particularly in research and development. Cash reserves have decreased, highlighting potential liquidity risks moving forward.
Read more →IFRXInflaRx to Report Second Quarter 2025 Results on August 7, 2025
InflaRx N.V. will report its second quarter 2025 financial results on August 7, 2025, before market opening. The company, known for its anti-inflammatory therapeutics, is advancing treatments targeting the complement system. Notably, it has developed vilobelimab, a first-in-class monoclonal antibody, and is also working on INF904, an oral small molecule inhibitor.
Read more →IFRXInflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx N.V. has received a notice from Nasdaq indicating that its stock price has fallen below the minimum requirement of $1.00 per share for continued listing. The company has 180 days to regain compliance, or it may consider transferring to the Nasdaq Capital Market for an additional 180 days. The notice does not affect current trading but highlights significant compliance challenges ahead.
Read more →IFRXInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
InflaRx N.V. announced that the Phase 3 trial for vilobelimab in pyoderma gangrenosum was halted by the Independent Data Monitoring Committee due to futility. Despite no adverse events reported, the company will discontinue this indication and focus on its other candidate, INF904. The company aims to extend its cash runway amidst these challenges.
Read more →IFRXInflaRx to Participate in Upcoming Investor Conferences
InflaRx N.V. will participate in several investor conferences in June and July 2025, including the Jefferies Global Healthcare Conference and the Oppenheimer Innovators in I&I Summit. The company will conduct presentations and one-on-one meetings with investors, showcasing its advancements in anti-inflammatory therapeutics. InflaRx's lead product candidate, vilobelimab, is a first-in-class monoclonal antibody targeting C5a.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2025 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
InflaRx N.V. released its unaudited condensed consolidated financial statements for the first quarter of 2025, revealing a loss of €8.3 million. Despite having €47.3 million in cash and cash equivalents, the company faces increased liabilities and ongoing operational losses. They did manage to issue more shares during this quarter, which contributed to a slight improvement in capital. However, the overall financial picture appears concerning as costs continue to exceed revenues significantly.
Read more →IFRXInflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
InflaRx N.V. reported its Q1 2025 financial results, highlighting key advancements in its pipeline. The company successfully completed required toxicology studies for INF904, while an interim analysis for vilobelimab's Phase 3 trial is anticipated soon, potentially impacting its trial strategy. Financially, InflaRx maintains a healthy cash balance of €65.7 million, sufficient to cover operations until 2027. However, the company continues to face challenges with no product sales revenue reported for the period, alongside an overall net loss.
Read more →IFRXInflaRx to Report First Quarter 2025 Results on May 7, 2025
InflaRx N.V. has announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, prior to market opening. The company is focused on developing anti-inflammatory therapies, with its lead product candidate, vilobelimab, showing promising clinical efficacy. No conference call will be held following the announcement. InflaRx operates globally, with subsidiaries in both Germany and the USA.
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2025 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has issued a convening notice for its 2025 annual general meeting (AGM) scheduled on April 24, 2025. The notice includes details regarding attendance requirements for shareholders and beneficial owners, as well as the agenda items for the AGM. Key topics include the adoption of the company's annual accounts for fiscal year 2024, the appointment of KPMG as the external auditor, and proposals regarding share capital and liability releases for directors. Important pre-meeting processes, such as proxy issuance and attendance notifications, are also outlined.
Read more →IFRXInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones Received European Commission approval for GOHIBIC (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory dis
InflaRx N.V. reported its financial results for 2024, highlighting significant achievements including EU marketing authorization for GOHIBIC (vilobelimab) as the first treatment for SARS-CoV-2-induced ARDS. The company anticipates major milestones in 2025, such as interim analysis for vilobelimab in pyoderma gangrenosum and topline data for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa. Financially, InflaRx is on stable ground with a cash runway extending into 2027, despite increased costs and challenges in R&D expenditures.
Read more →IFRXInflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
InflaRx N.V. presented promising data on vilobelimab at the 2025 AAD Annual Meeting, highlighting its efficacy and safety in treating pyoderma gangrenosum and hidradenitis suppurativa. The company reported multiple analyses demonstrating significant reductions in C5a levels, which are crucial mediators of inflammation. Notably, vilobelimab was well-tolerated with no serious safety concerns. The findings bolster the drug's potential as a treatment option for these inflammatory skin conditions.
Read more →IFRXInflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
InflaRx N.V. announced that all abstracts submitted for vilobelimab have been accepted for presentation at the 2025 AAD Annual Meeting. The meeting will highlight key findings pertaining to vilobelimab's role in treating pyoderma gangrenosum and hidradenitis suppurativa. Dr. Camilla Chong emphasized the significance of their research, particularly in demonstrating a reduction in draining tunnels in hidradenitis suppurativa patients. Vilobelimab, a monoclonal antibody, is also being developed for various inflammatory conditions and has received orphan drug designation by the FDA and EMA.
Read more →IFRXInflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
InflaRx N.V. has announced its intention to publish financial results for Q4 and the full year 2024 on March 20, 2025. Additionally, the company is set to participate in two upcoming investor conferences, including a fireside chat at the Leerink Global Healthcare Conference and a virtual session at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference. The firm focuses on developing anti-inflammatory therapies targeting the complement system, with its lead candidate vilobelimab showing promise in multiple clinical studies.
Read more →IFRXInflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
InflaRx N.V. announced the completion of its public offering of 8,250,000 ordinary shares, raising approximately $30 million. The funds will primarily be used to support clinical development of its drug candidates, including vilobelimab and INF904. The offering included pre-funded warrants for additional shares, with underwriters granted a 30-day purchase option for extra shares. The company has a history of pioneering anti-inflammatory therapeutics and intends to leverage the new funds for growth and expansion of its product pipeline.
Read more →IFRXInflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
InflaRx N.V. announced the pricing of a public offering of 8.25 million ordinary shares at $2.00 each, along with pre-funded warrants for an additional 6.75 million shares. The offering is expected to close on February 18, 2025, subject to customary conditions. Proceeds will be primarily utilized for clinical development of their therapeutic pipeline, which includes vilobelimab and INF904. Guggenheim Securities is the book-running manager for the offering.
Read more →IFRXInflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
InflaRx N.V. has initiated a public offering of ordinary shares and pre-funded warrants aimed at raising capital for the clinical development of its pipeline candidates, including vilobelimab and INF904. The offering will be managed by Guggenheim Securities and is subject to market conditions, presenting some uncertainty regarding its completion and terms. The net proceeds will primarily support clinical programs and general corporate purposes.
Read more →IFRXInflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
InflaRx N.V. has announced its participation in the Guggenheim SMID Cap Biotech Conference scheduled for February 5-6, 2025, in New York. The company focuses on anti-inflammatory therapeutics, utilizing proprietary technologies to target the complement system. Its lead product candidate, vilobelimab, is a first-in-class monoclonal antibody that has shown promising clinical results in various inflammatory diseases. InflaRx was established in 2007 and operates in both Germany and the USA.
Read more →IFRXInflaRx Receives European Commission Approval for GOHIBIC (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) Jena, Germany
InflaRx N.V. has received European Commission approval for GOHIBIC (vilobelimab), making it the first treatment authorized in the EU for adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) requiring invasive mechanical ventilation. The approval follows promising results from the multicenter Phase 3 PANAMO trial, which showed a significant improvement in survival compared to placebo. The authorization is valid across all 27 EU member states plus Iceland, Liechtenstein, and Norway, positioning InflaRx to explore commercial partnerships. GOHIBIC has also received an Emergency Use Authorization from the FDA in the U.S.
Read more →IFRXInflaRx Announces Participation in January Events in San Francisco
InflaRx N.V. has announced its participation in several significant events in San Francisco during the week of January 13, 2025, alongside the 43rd Annual J.P. Morgan Healthcare Conference. Among these are 1-on-1 meetings and a workshop addressing the need for innovative responses to emerging disease threats. The company is noted for its development of anti-inflammatory therapeutics targeting the complement system, particularly its lead product candidate, vilobelimab. The announcement reflects the company's ongoing efforts to engage with industry participants and highlight its scientific advancements.
Read more →IFRXInflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 Jena, Germany
InflaRx N.V. has announced the dosing of the first patient in its Phase 2a study for the oral C5aR inhibitor INF904, focusing on chronic spontaneous urticaria and hidradenitis suppurativa. The trial aims to include 75 patients and will assess various dosing regimens over four weeks. The study is expected to provide crucial safety and pharmacokinetic data and may inform a larger Phase 2b study planned for late 2025. Camilla Chong, the Chief Medical Officer, expressed optimism about the drug's potential to meet unmet medical needs in inflammation-related conditions.
Read more →IFRXInflaRx Receives Positive CHMP Opinion for GOHIBIC (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome Jena, Germany
InflaRx has received a positive opinion from the CHMP recommending marketing authorization for GOHIBIC (vilobelimab) for treating SARS-CoV-2-induced acute respiratory distress syndrome. This recommendation comes under exceptional circumstances, highlighting the urgent need for effective treatments in ICU patients. GOHIBIC previously received Emergency Use Authorization from the FDA and has shown promising results in clinical trials, demonstrating a significant reduction in mortality. The company plans to commercialize GOHIBIC in Europe and provide ongoing clinical updates as part of its regulatory obligations.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2024 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
InflaRx N.V. released unaudited condensed consolidated financial statements for the three and nine months ending September 30, 2024. The company reported a notable increase in revenues to 123,819 euros for Q3 2024, compared to 60,803 euros in Q3 2023. However, InflaRx experienced significant losses, with a net loss of 40,952,630 euros for the nine-month period. Total assets and equity also declined from earlier periods, contributing to concerns about the company's financial health and operational results.
Read more →IFRXInflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
InflaRx N.V. reported its third-quarter financial results, highlighting significant progress in its vilobelimab Phase 3 trial and the expected initiation of a Phase 2a trial for INF904 by year's end. With a robust cash reserve of €62 million, the company is positioned to sustain operations into 2026. The review of vilobelimab by the European CHMP is ongoing, with opinions expected mid-November, while the company prepares for anticipated data readouts in 2025. Overall, InflaRx continues to strengthen its competitive position in complement inhibition.
Read more →IFRXInflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
InflaRx N.V. has announced it will report its third quarter 2024 financial results on November 8, 2024, prior to market opening. The company will not hold a conference call but will participate in the Guggenheim Securities Inaugural Healthcare Innovation Conference from November 11-13, 2024, in Boston. The conference includes a fireside chat and one-on-one meetings to enhance investor engagement. InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead candidate, vilobelimab, showing promising potential in clinical studies.
Read more →IFRXInflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
InflaRx N.V. presented a post hoc analysis of its SHINE Phase 2b study on vilobelimab at the 2024 EADV Congress. The analysis demonstrated significant reductions in draining tunnels and lesion counts in patients with hidradenitis suppurativa, suggesting a potential clinical benefit for the treatment. The findings also indicated a need for additional efficacy parameters to better understand vilobelimab's impact on this condition, which affects patients' quality of life.
Read more →IFRXInflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx N.V. presented new preclinical data for its oral C5aR inhibitor, INF904, during the 2024 European Meeting on Complement in Human Diseases. The findings demonstrated INF904's effectiveness in reducing inflammatory responses in various preclinical models, showing superior pharmacokinetic properties compared to existing treatments. The company also highlighted its commitment to advancing anti-inflammatory therapeutics and shared insights from its research at the conference.
Read more →IFRXInflaRx Announces Participation in September Investor Events
InflaRx N.V. has announced its participation in two upcoming investor conferences in September 2024, taking place in New York City. The firm will present an on-demand virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference and will conduct a fireside chat at the 2024 Cantor Global Healthcare Conference. These events will provide opportunities for one-on-one meetings with investors, enhancing InflaRx's outreach and potential for investor engagement.
Read more →IFRXInflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
InflaRx N.V. has reported its financial results for the second quarter of 2024, highlighting progress in its clinical pipeline. A Phase 2a study for the oral C5aR inhibitor INF904 is expected to begin by the end of 2024, targeting chronic spontaneous urticaria and hidradenitis suppurativa. Additionally, vilobelimab has been selected for a BARDA-sponsored Phase 2 trial for acute respiratory distress syndrome. The company maintains a cash runway into 2026, although product sales remain limited.
Read more →IFRXInflaRx N.V. Unaudited Condensed Consolidated Financial Statements
InflaRx N.V. released its unaudited consolidated financial statements for the six months ending June 30, 2024, revealing significant losses amounting to €23.5 million. The company's total assets also fell dramatically from €120.2 million to €93.0 million during this period. The financial report indicates rising sales and marketing expenses and research and development costs, indicating increased operational expenditures despite the drop in revenues. Overall, the company appears to be in a challenging financial position as it navigates these losses.
Read more →IFRXInflaRx to Report Second Quarter 2024 Results on August 8, 2024
InflaRx N.V. has announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, prior to market opening. The company specializes in anti-inflammatory therapeutics, utilizing its proprietary technologies to target complement activation. One of its leading products, vilobelimab, has shown clinical efficacy across various indications. However, no conference call is planned following the results announcement.
Read more →IFRXInflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx N.V. will present new preclinical data on its oral C5aR inhibitor, INF904, at the upcoming 2024 European Meeting on Complement in Human Diseases in Lübeck, Germany. The presentations include promising findings regarding INF904's anti-inflammatory effects in disease models and its favorable safety profile based on initial human studies. InflaRx will also engage in panel discussions and symposiums, emphasizing their commitment to translating scientific advancements into therapeutic options. The event is set to further showcase the evolving landscape of complement-mediated therapies.
Read more →IFRXInflaRx N.V. Ordinary Shares (nominal value 0.12 per share)
InflaRx N.V. has entered an agreement with Leerink Partners LLC to issue and sell ordinary shares valued up to $75 million. This move follows the effectiveness of their registration statement with the Securities and Exchange Commission, allowing the company to raise capital as needed. Each issuance will follow specific parameters set forth in their agreement, indicating a careful approach to managing their share sales.
Read more →IFRXInflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) Jena, Germany
InflaRx N.V. announced that its investigational drug GOHIBIC (vilobelimab) has been selected for the first BARDA-sponsored clinical trial focused on acute respiratory distress syndrome (ARDS). This Phase 2 study, involving 600 hospitalized adults, aims to evaluate vilobelimab's safety and efficacy against placebo. The trial represents an important step in addressing the critical unmet medical need for ARDS therapies, as no approved treatments currently exist. InflaRx's CEO expressed optimism about the potential impact of vilobelimab in managing ARDS, viewing this trial as a vital opportunity to further its research in host-directed therapeutics.
Read more →IFRXInflaRx Hosts R&D Event Highlighting the Promise of INF904 Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong d
InflaRx N.V. hosted a virtual R&D event focused on their oral small molecule C5aR inhibitor, INF904. Expert speakers provided insights into its potential role in treating chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), highlighting the drug's promise and expected clinical trial progress. A Phase 2a trial is set to begin by the end of 2024, targeting significant unmet medical needs in immuno-dermatology. The company believes INF904 could be a best-in-class therapy, with further developments expected in 2025.
Read more →IFRXInflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators Jena, Germany
InflaRx recently presented new post-hoc analysis data from their PANAMO Phase III trial at the ATS 2024 International Conference. The analysis highlights the combined use of vilobelimab with tocilizumab or baricitinib in critically ill COVID-19 patients, showing an 84.6% reduction in 28-day all-cause mortality rates. This combination therapy not only demonstrated improved mortality outcomes but was also deemed safe without significant concerns. InflaRx emphasizes vilobelimab's potential life-saving role in acute COVID-19 care and outlines ongoing developments in various inflammatory conditions.
Read more →IFRXInflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
InflaRx N.V. reported its financial results for Q1 2024 and provided an update on its drug development progress. The company is moving forward with its Phase IIa study for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa, with results expected in 2025. Additionally, an interim analysis for the Phase III trial of vilobelimab in pyoderma gangrenosum is anticipated in 2025. InflaRx is also set to host a virtual R&D event to discuss future developments and opportunities in immuno-inflammation.
Read more →IFRXInflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
InflaRx N.V. plans to report its first quarter 2024 results on May 8, 2024, and will hold a virtual R&D event on June 5, 2024. The event will focus on the development of INF904, an oral small molecule C5aR inhibitor, and its applications in chronic spontaneous urticaria and hidradenitis suppurativa. Renowned experts in dermatology and systemic inflammation will lead discussions on clinical trial expectations and commercial opportunities.
Read more →IFRXInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
InflaRx N.V. announced its participation in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event in New York City. The company will partake in a panel titled 'New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia' scheduled for May 14, 2024. This event aims to showcase developments in biopharma, particularly concerning anti-inflammatory therapies, including InflaRx's lead candidate vilobelimab. The participation highlights InflaRx's commitment to advancing treatments for various inflammatory diseases.
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2024 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has announced its 2024 annual general meeting (AGM) set for April 25, 2024, in Amsterdam. The agenda includes the discussion of the financial report for 2023, votes on annual accounts, directors' reappointments, and authorization extensions for the board. Shareholders are required to submit Attendance Notices to participate in the AGM. The record date for eligibility is March 28, 2024.
Read more →IFRXInflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vil
InflaRx N.V. has announced its financial results for the fiscal year 2023 and provided an update on the development of its therapeutic candidate INF904. The company aims to concentrate on immuno-dermatology, targeting chronic inflammatory conditions such as chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) with INF904, which is an oral C5aR inhibitor. Additionally, the development of vilobelimab for ulcerative pyoderma gangrenosum is progressing well. InflaRx plans to initiate a Phase IIa study for INF904 before the end of 2024, positioning itself to address significant unmet medical needs in these fields.
Read more →IFRXCORPORATE PRESENTATION MARCH 2024 Important Notice and Disclaimer This presentation has been prepared by InflaRx N.V. ("InflaRx" or the "Company"). This presentation is made for informational purposes only and does not c
InflaRx N.V. has prepared a corporate presentation outlining its forward-looking statements and product developments. The company emphasizes its lead candidate, vilobelimab, as a treatment for COVID-19 and other inflammatory conditions, while also detailing its research into INF904. InflaRx highlights the significance of its proprietary anti-C5a and C5aR technologies, aiming for commercialization in the biopharma market. The presentation features disclaimers regarding reliance on forward-looking statements and information sources related to clinical data.
Read more →IFRXInflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
InflaRx N.V. will hold a conference call on March 21, 2024, to discuss its development plans for INF904, an oral C5aR inhibitor. The company will also report its financial results for Q4 and the full year of 2023. With a focus on anti-inflammatory therapeutics, InflaRx is positioning itself strategically within the biopharmaceutical landscape, especially with its promising product candidates. This call comes as InflaRx aims to enhance stakeholder engagement and transparency in its operations.
Read more →IFRXInflaRx Appoints Jan Medina as Head of Investor Relations
InflaRx N.V. has appointed Jan Medina as Vice President and Head of Investor Relations. Mr. Medina, who has over 25 years of experience in the life sciences sector, will focus on strengthening the company's ties with investors. His appointment comes at a time when InflaRx is advancing its clinical programs, including the promising oral C5aR inhibitor INF904 and the late-stage asset vilobelimab. These developments aim to improve treatment options for chronic immune-inflammatory diseases.
Read more →IFRXInflaRx Announces Initiation of its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use
InflaRx Pharmaceuticals has launched the Commitment Program for GOHIBIC (vilobelimab) to reimburse costs for up to six doses for eligible patients who died from COVID-19 while receiving the treatment in line with its Emergency Use Authorization. This initiative aims to encourage hospitals in the U.S. to administer GOHIBIC, which has shown potential in reducing mortality rates in critically ill COVID-19 patients. While the program represents a significant step towards improving access to this treatment, it is important to note that GOHIBIC has yet to receive full FDA approval.
Read more →IFRXInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over teste
InflaRx N.V. has announced positive topline results from the Phase I study of their C5aR inhibitor, INF904, demonstrating promising pharmacokinetic and pharmacodynamic profiles. The study involved 24 participants receiving multiple doses, with results indicating the drug was well tolerated and achieved effective inhibition of C5a-induced signaling. InflaRx plans to advance INF904 into Phase II clinical development towards the end of 2024, following encouraging preliminary data from the single ascending dose part of the study. No safety signals of concern were reported, further solidifying the potential for this therapy in chronic immune-inflammatory conditions.
Read more →IFRXInflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and firs
InflaRx N.V. has announced the dosing of the first patient in its Phase III trial studying vilobelimab for ulcerative pyoderma gangrenosum, a rare and painful skin condition. This pivotal study, which involves a multi-national, randomized, and double-blind design, aims to determine the efficacy and safety of vilobelimab compared to placebo. Notably, there are currently no approved treatments for this condition in the U.S. or Europe, highlighting the study's importance. The trial is set to enroll patients across various countries and incorporates an adaptive trial design to optimize outcomes based on interim analyses.
Read more →IFRXInflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
InflaRx N.V. recently reported its financial results for Q3 2023, highlighting significant progress in its clinical development programs. The company announced favorable Phase I data for its C5aR inhibitor, INF904, and initiated a Phase III trial for vilobelimab in pyoderma gangrenosum. Additionally, the EMA validated a marketing authorization application for vilobelimab targeting COVID-19-related ARDS. However, InflaRx has halted development of vilobelimab for cutaneous squamous cell carcinoma to focus resources on other promising indications.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2023 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
InflaRx N.V. has published its unaudited condensed consolidated financial statements for the quarter ending September 30, 2023. The company reported total revenues of €60,803 but significant operating losses of €11,150,854. Accumulated deficit has risen to €270,197,663 amid high expenses in research and development. The financial situation presents a challenging outlook with increased cash usage in operations.
Read more →IFRXInflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 SAD data confirm best-in-class potential for INF904 as orally administered C5aR inhibitor: o Safety
InflaRx N.V. announced positive topline results from the Phase I study of INF904, an orally administered C5aR inhibitor. The study showed excellent safety and tolerability with no serious adverse events reported across a range of dosages. Notably, the drug demonstrated favorable pharmacokinetic and pharmacodynamic profiles, reinforcing its potential as a best-in-class treatment for chronic inflammatory conditions. The company is now preparing for further clinical evaluations and anticipates results from the second part of the trial in early 2024.
Read more →IFRXInflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) MAA for vilobelimab was submitted in July MAA has been
InflaRx N.V. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vilobelimab, aimed at treating critically ill COVID-19 patients requiring invasive mechanical ventilation. The EMA has validated the MAA, which is now under regulatory review by the European Committee for Medicinal Products for Human Use. The submission is based on promising results from the Phase III PANAMO trial, demonstrating significant improvements in patient survival compared to placebo. Additionally, vilobelimab has received Emergency Use Authorization in the U.S. for similar indications.
Read more →IFRXInflaRx Reports Second Quarter 2023 Financial Results & Operating Update
InflaRx N.V. reported its financial results for Q2 2023, highlighting the Emergency Use Authorization and launch of Gohibic (vilobelimab) for COVID-19 treatment in the U.S. The company is advancing its oral C5aR inhibitor, INF904, through clinical trials while also making strides in other indications such as cutaneous squamous cell carcinoma and pyoderma gangrenosum. With a strong cash position, InflaRx aims to continue expanding its clinical development under the leadership of newly appointed CMO Dr. Camilla Chong.
Read more →IFRXInflaRx Appoints Dr. Camilla Chong as Chief Medical Officer Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug development Dr. Chong to lead clinical development
InflaRx has announced the appointment of Dr. Camilla Chong as Chief Medical Officer, effective July 1, 2023. Dr. Chong has extensive experience in drug development and will oversee the company's clinical development activities. Her leadership comes at a crucial time as InflaRx prepares for the commercial launch of its first product, Gohibic (vilobelimab), following a recent Emergency Use Authorization by the FDA. The company is focused on treating acute inflammatory conditions and chronic immunological diseases.
Read more →IFRXInflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients Gohibic is now commercially available for hospitals in the U.S. Gohibic can be used under an
InflaRx N.V. has announced the commercial launch of Gohibic (vilobelimab) in the U.S. for the treatment of critically ill COVID-19 patients. This follows the drug's Emergency Use Authorization granted by the FDA. Gohibic is notable for its ability to reduce all-cause mortality in patients requiring invasive mechanical ventilation. The company is actively pursuing further regulatory approvals to expand the drug's availability.
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2023 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
InflaRx N.V. released its unaudited condensed financial statements for the three months ending March 31, 2023. The company reported a substantial loss of €11,083,833 compared to a loss of €14,002,030 in the same period of 2022. Operating expenses increased notably, driven by a rise in research and development costs. Additionally, the company saw a significant decline in cash reserves, dropping from over €16 million at the start of the quarter to just over €2 million by its end.
Read more →IFRXInflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
InflaRx reported its financial and operational results for Q1 2023, highlighting the Emergency Use Authorization (EUA) granted for Gohibic (vilobelimab) for critically ill COVID-19 patients. The company is preparing to make Gohibic available in the U.S. shortly, anticipating revenue from sales as early as Q3 2023. InflaRx is also advancing its pipeline with an ongoing Phase III study for vilobelimab in pyoderma gangrenosum and evaluating the drug in cutaneous squamous cell carcinoma. With a cash position of approximately €72.3 million, InflaRx aims to support its development activities and increase its market presence.
Read more →IFRXInflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
InflaRx N.V. has successfully completed its underwritten public offering, raising approximately $46 million after the full exercise of a greenshoe option. The company plans to use the net proceeds for the continued development of its anti-inflammatory drug vilobelimab, as well as for general research, development expenses, and corporate purposes. This move reflects strong market interest and support for IvlaRx's initiatives in biopharmaceuticals. The offering was managed by Raymond James & Associates and LifeSci Capital.
Read more →IFRXInflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
InflaRx N.V. has completed its $40 million public offering of 9,411,765 ordinary shares at a price of $4.25 each. The proceeds will be utilized to advance the development of vilobelimab, cover general research and development expenses, and bolster the company's commercial infrastructure. Additionally, the underwriters have a 30-day option to purchase more shares. The offering is structured under an effective shelf registration declared by the SEC.
Read more →IFRXInflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
InflaRx N.V. has announced the pricing of a public offering totaling $40 million, with each ordinary share priced at $4.25. The offering is expected to close on April 14, 2023, pending standard closing conditions. The proceeds will be utilized for the continued development of vilobelimab, as well as for general research and corporate purposes. Raymond James & Associates is the sole book-running manager for the offering, with additional shares available for underwriters to purchase under certain conditions.
Read more →IFRXInflaRx Announces Public Offering of Ordinary Shares
InflaRx N.V. has announced a public offering of ordinary shares aimed at financing the continued development of its anti-inflammatory therapeutic vilobelimab. The completion and terms of this offering remain uncertain as it is contingent on market conditions. The company plans to use the proceeds for general research, development, and investments in its commercial infrastructure. The offering includes a provision for underwriters to purchase additional shares, potentially signaling investor interest in the company's future.
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2023 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
InflaRx N.V. has issued a convening notice for its 2023 annual general meeting (AGM) scheduled for April 26, 2023, in Amsterdam. The agenda includes the adoption of annual accounts for fiscal year 2022 and proposes the appointment of Ernst & Young as independent auditors. It also involves a binding nomination of Ms. Hege Hellstrom as a non-executive director. Additionally, shareholders are reminded of proxy participation requirements and deadlines.
Read more →IFRXInflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays
InflaRx N.V. announced that its monoclonal antibody Gohibic (vilobelimab) received Emergency Use Authorization (EUA) from the FDA for treating hospitalized COVID-19 patients who require invasive mechanical ventilation. The authorization is based on clinical data from the PANAMO trial, which demonstrated a significant reduction in mortality rates among patients treated with Gohibic. The company is also pursuing regulatory approval in Europe and expanding Gohibic's use in other indications. Despite the positive news, concerns remain regarding the overall approval status and limited safety data available for the drug.
Read more →IFRXInflaRx Reports Full Year 2022 Financial and Operating Results Major progress in development of vilobelimab o Phase III study in PG announced following detailed feedback and recommendations from the U.S. Food and Drug Ad
InflaRx has reported positive financial and operational results for the year ended December 31, 2022, highlighting significant advancements in their lead drug candidate, vilobelimab. Following comprehensive FDA feedback, the company has submitted a Phase III trial protocol for vilobelimab's use in treating Pyoderma Gangrenosum (PG) and is also pursuing an EUA for COVID-19 treatment. Plans are in place for additional clinical trials, including a Phase I study of a new C5a receptor inhibitor. The organization expresses optimism about its prospects, driven by recent clinical successes and funding support.
Read more →IFRXInflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients Multi-national, randomized, controlled adaptive Pha
InflaRx N.V. has announced the design details for a planned Phase III study of vilobelimab aimed at treating ulcerative pyoderma gangrenosum (PG), a challenging condition with no approved therapies. The trial will be multinational and includes interim analysis to adapt the sample size based on outcomes. Positive results from a previous Phase IIa study have been highlighted, where a notable percentage of patients experienced complete ulcer closure. Additionally, the company's request for Emergency Use Authorization (EUA) for vilobelimab concerning critically ill COVID-19 patients is still under FDA evaluation.
Read more →IFRXInflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19 InflaRx will provide acce
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19 Jena, Germany, December 21, 2022 - InflaRx N.V. (Nasdaq: IFRX) (the "Company" or "In
Read more →IFRXInflaRx Reports Third Quarter 2022 Financial & Operating Results
Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA) PANAMO Phase III study results in severe CO
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Ph
Read more →IFRXInflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiated Study designed as s
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 Jena, Germany, November 9, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announ
Read more →IFRXInflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients Company also earns FDA Fast Track designation for vilobelimab to treat critically ill CO
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients Jena, Germany, September 29, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeut
Read more →IFRXInflaRx to Present at Upcoming Scientific and Investor Conferences
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences. H.C. Wainwright 24th
Read more →IFRXInflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine The Lancet Respiratory Medicine , a peer-reviewed journal, published the results of the PAN
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine Jena, Germany, September 08, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics
Read more →IFRXInflaRx Reports Second Quarter 2022 Financial & Operating Results
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDA Plans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announced Grant income of €14.4 million realized during the second quarter Cash, cash equ
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its who
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmac
Read more →IFRXInflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients Completed encouraging Type B meeting with US FDA Application for EUA plan
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients Jena, Germany, July 26, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory
Read more →IFRXInflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum Fast track f
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum Jena, Germany, July 6, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today
Read more →IFRXInflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19 Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II me
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19 Jena, Germany, June 29, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, p
Read more →IFRXInflaRx to Present at the H.C. Wainwright Global Investment Conference
JENA, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2022 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharm
Read more →IFRXInflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
Quarter highlighted by progress with vilobelimab in several indications: Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway Final data from Phase IIa open-label study in patients with pyoderma
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2022 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
This is the convening notice for the 2022 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on April 28, 2022 at 9:00 hours Amsterdam time (CEST) at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, Schiphol, 1118 BN, Schiphol, the Nether
Read more →IFRXInflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients Jena, Germany, March 31, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting th
Read more →IFRXInflaRx Reports Full Year 2021 Financial and Operating Results Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa Positive Phase IIa data reported with vilobelim
InflaRx Reports Full Year 2021 Financial and Operating Results Jena, Germany, March 24, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and ope
Read more →IFRXInflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa Jena, Germany
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa Jena, Germany, March 17, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeti
Read more →IFRXInflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting Jena, Germany
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting Jena, Germany, March 8, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by
Read more →IFRXInflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa Jena, Germany
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa Jena, Germany, February 28, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, toda
Read more →IFRXInflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort h
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma Jena, Germany, February 16, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting th
Read more →IFRXInflaRx to Present at Annual SVB Leerink Global Health Conference
JENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11th Annual SVB Leerink Healthcare Conference being held virt
Read more →IFRXInflaRx Announces New Pipeline Program - Oral C5aR Inhibitor Regulatory discussions on Phase I program have been initiated First-in-human study expected to start in the second half of 2022 Jena, Germany
InflaRx Announces New Pipeline Program - Oral C5aR Inhibitor Jena, Germany, January 10, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline pr
Read more →IFRXInflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
Presentation at J.P. Morgan Healthcare Conference on January 13th Corporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10th Company to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany,
Read more →IFRXInflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa Phase III study to include a new primary endpoint, the modified HiSCR New primary endpoint and Phase III trial design to be discus
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa Jena, Germany, January 5, 2022 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today
Read more →IFRXInflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV) Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV) Jena, Germany, November 15, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the
Read more →IFRXInflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
JENA, Germany, Nov. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of
Read more →IFRXINFLARX N.V. UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2021 These unaudited interim condensed financial statements are consolidated financial statements for the group consisting of Inf
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2021 These unaudited interim condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany
Read more →IFRXInflaRx Reports Third Quarter 2021 Financial & Operating Results
Feedback received from FDA supportive of new primary endpoint measuring reductions in all three inflammatory Hidradenitis Suppurativa (HS) lesions for Phase III program with vilobelimab in HS In Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum, 6 out of 7 pat
Read more →IFRXInflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
JENA, GERMANY, Nov. 03, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that Prof. Niels C. Riedemann, Chief Executive Officer and Founder of
Read more →IFRXInflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum 6 out of 7 patients (85.7%) showed clinical remission (PGA score 1) and closure of target ulcer in
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum Jena, Germany, October 27, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targe
Read more →IFRXInflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19 Initial portion of the grant amounts to EUR 25.8 million Re
InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19 Jena, Germany, October 19, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing a
Read more →IFRXInflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 Study has enrolled 369 patients across 9 countries Topline results expected to be available in Q1 2022 Jena, Germany
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 Jena, Germany, October 12, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today
Read more →IFRXInflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will pr
Read more →IFRXInflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint Jena, Germany, September 8, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting th
Read more →IFRXCONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
This is the convening notice for the extraordinary general meeting of shareholders of InflaRx N.V. (the "Company") to be held on August 25, 2021 at 9:00 hours CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "EGM"). The agend
Read more →IFRXInflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum Four out of 10 evaluable patients showed clinical response (PGA score 3), three
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum Jena, Germany, August 10, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory the
Read more →IFRXInflaRx to Present at the BTIG Virtual Biotechnology Conference
JENA, Germany, Aug. 06, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the BTIG Virtual Biotechnology Conference on August 10. A BTIG analys
Read more →IFRXInflaRx Reports Second Quarter 2021 Financial & Operating Results
Severe COVID-19 trial enrollment reaches 299 patients; an independent data monitoring committee has recommended to continue the trial as planned after analyzing data from the first 180 evaluable patients Type A meeting request submitted to further discuss primary endpoint for th
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2021 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its who
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2021 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharma
Read more →IFRXInflaRx to Present at the Raymond James Human Health Innovation Conference
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the Raymond James Human Health Innovation Conference be
Read more →IFRXInflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab Jena,
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab Jena, Germany, June 8, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting t
Read more →IFRXTony Gibney Joins InflaRx Board of Directors Jena, Germany
Tony Gibney Joins InflaRx Board of Directors Jena, Germany, May 21, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced Mr. Tony Gibney has been appointed as
Read more →IFRXInflaRx Reports First Quarter 2021 Financial & Operating Results
Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase III clinical development of vilobelimab in Hidradenitis Suppurativa Vilobelimab
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2021 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2021 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharm
Read more →IFRXInflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tol
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study Jena, Germany, May 11, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2021 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
This is the convening notice for the 2021 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on May 19, 2021 at 14:00 hours CEST at Hilton Amsterdam Airport Schiphol, Schiphol Boulevard 701, Schiphol, 1118 BN, Schiphol, the Netherlands (the "AGM").
Read more →IFRXInflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with f
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum Jena, Germany, April 15, 2021 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced
Read more →IFRXInflaRx Reports Full Year 2020 Financial & Operating Results Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021 Phase III trial in
InflaRx Reports Full Year 2020 Financial & Operating Results Jena, Germany, March 25, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for th
Read more →IFRXInflaRx to Present at Upcoming Investor Conferences
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences C
Read more →IFRXInflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of 15,000
Read more →IFRXInflaRx N.V. 15,000,000 Common Shares Warrants to Purchase up to 15,000,000 Common Shares Underwriting Agreement
15,000,000 Common Shares Warrants to Purchase up to 15,000,000 Common Shares Underwriting Agreement Guggenheim Securities, LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Guggenheim Securities, LLC Ladies and Gentlemen: InflaRx N.V., a pu
Read more →IFRXInflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 15,000,000 com
Read more →IFRXInflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of common s
Read more →IFRXInflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction in inflammatory lesion counts and scores Data support continued development o
Read more →IFRXInflaRx Provides Update on Vilobelimab (IFX-1) Development Multiple data readouts expected in 2021 Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 Jena, Germa
InflaRx Provides Update on Vilobelimab (IFX-1) Development Jena, Germany, January 11, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today provided an update on the ongoing
Read more →IFRXInflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference being
Read more →IFRXInflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis Jena, Germany
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis Jena, Germany, January 5, 2021 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement sys
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2020 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2020 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx P
Read more →IFRXInflaRx Reports Q3 2020 Financial & Operating Results
Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumonia Published encouraging data from Phase II part of COVID-19 trial in The Lancet Rheumatology Announced leadership team additions Cash, cash equi
Read more →IFRXInflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer Thomas Taapken, Ph.D. appointed Chief Financial Officer Jordan Zwick promoted to Chief Strategy Officer Jena,
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer Jena, Germany, 17 September 2020 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complem
Read more →IFRXInflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia First site initiated for enrollment in the Netherlands Regulatory approval granted to start tr
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia Jena, Germany, 14 September 2020 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by target
Read more →IFRXInflaRx to Present at Upcoming Virtual Investor Events Jena, Germany
InflaRx to Present at Upcoming Virtual Investor Events Jena, Germany, August 6, 2020 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual i
Read more →IFRXInflaRx Reports Q2 2020 Financial & Operating Results
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate Completed end-of-Phase II meeting with the FDA for IFX-1 in hi
Read more →IFRXInflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trial Subject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III pa
Read more →IFRXAnnounces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia Jena, Germany, 21 July 2020 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announc
Read more →IFRXInflaRx N.V. Common Shares (nominal value 0.12 per share)
(nominal value 0.12 per share) 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: InflaRx N.V., a public limited liability company (naamloze vennootschap) under Dutch law (the "Company"), confirms its agreement (this "Agreement") with SVB
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2020 annual general meeting of shareholders of InflaRx N.V. (the " Company ") to be held on
This is the convening notice for the 2020 annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on July 16, 2020 at 14:00 hours CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda fo
Read more →IFRXInflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19 IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, a
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19 Jena, Germany, 17 June 2020 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therape
Read more →IFRXInflaRx Reports Q1 2020 Financial & Operating Results
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Signed clinical collabor
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2020 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2020 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, and InflaRx Pharmaceutical Inc.,
Read more →IFRXInflaRx Reports Full Year 2019 Financial & Operating Results End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraeno
InflaRx Reports Full Year 2019 Financial & Operating Results Jena, Germany, 29 April 2020 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the
Read more →IFRXControlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020 Important Notice and DisclaimerThis presentation has been prepared by InflaRx N.V. ("InflaRx"), a US-Nasdaq publicly listed Dutch company having its p
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020 Important Notice and DisclaimerThis presentation has been prepared by InflaRx N.V. ("InflaRx"), a US-Nasdaq publicly listed Dutch company having its principle place of business in Germany. This presentation i
Read more →IFRXInflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx's anti-C5a Technology InflaRx has dosed the
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx's anti-C5a Technology Jena, Germany, March 31, 2020 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage bio
Read more →IFRXInflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum Two out of the first five patients dosed with IFX-1 achieved complete remission
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum Jena, Germany, February 26, 2020 - InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory the
Read more →IFRXInflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference
JENA, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 9th Annual SVB Leerink Global Healthcare Conference February
Read more →IFRXCONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020 IMPORTANT NOTICE AND DISCLAIMERThis presentation has been prepared by InflaRx N.V. ("InflaRx"), a US-Nasdaq publicly listed Dutch company having its
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020 IMPORTANT NOTICE AND DISCLAIMERThis presentation has been prepared by InflaRx N.V. ("InflaRx"), a US-Nasdaq publicly listed Dutch company having its principle place of business in Germany. This presentation
Read more →IFRXInflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the J.P. Morgan 38th Annual Healthcare Conference being held Janu
Read more →IFRXIFX-1 C5a Controlling inflammation Developing the First in Class Anti-C5a Antibody IFX-1: Lessons Learned from Clinical Trials Niels C. Riedemann Important Notice and Disclaimer THIS PRESENTATION HAS BEEN PREPARED BY INF
IFX-1 C5a Controlling inflammation Developing the First in Class Anti-C5a Antibody IFX-1: Lessons Learned from Clinical Trials Niels C. Riedemann Important Notice and Disclaimer THIS PRESENTATION HAS BEEN PREPARED BY INFLARX n.v. ("INFLARX"), a US-Nasdaq publicly listed Dutch
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and it
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - SEPTEMBER 30, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, and InflaRx Pharmaceutical I
Read more →IFRXInflaRx Reports Second Quarter 2019 Financial & Operating Results
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identified First patient treated in Pyoderma Gangraenosum phase IIa trial Second phase II clinical trial commenced in ANCA-associated vasculitis C
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its who
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - JUNE 30, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, and InflaRx Pharmaceutical Inc., A
Read more →IFRXInflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa Jena, Germany, July 18, 2019 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system
Read more →IFRXInflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers Jena, Germ
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum Jena, Germany, June 13, 2019 - InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement
Read more →IFRXInflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa - IFX-1 did not demonstrate a statistical significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) r
Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa Jena, Germany, June 5th, 2019 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, today reported the top-line resul
Read more →IFRXINFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wh
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - MARCH 31, 2019 These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, and InflaRx Pharmaceutical Inc.,
Read more →IFRXInflaRx Reports First Quarter 2019 Financial & Operating Results
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma Gangraenosum; first patient treated in AAV EU trial Corporate: U.S. operations expanded and new Non-Executiv
Read more →IFRXInflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe Jena, Germany, 14 May 2019 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company
InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe Jena, Germany, 14 May 2019 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting t
Read more →IFRXCONVENING NOTICE This is the convening notice for the 2019 annual general meeting of shareholders of InflaRx N.V. (the Company ) to be held on
This is the convening notice for the 2019 annual general meeting of shareholders of InflaRx N.V. (the Company ) to be held on May 23, 2019 at 3:00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the AGM ). The agenda for the
Read more →IFRXIFX-1 C5a Controlling inflammation Corporate Presentation May 2019 Important Notice and Disclaimer THIS PRESENTATION HAS BEEN PREPARED BY INFLARX n.v. ("INFLARX"), a US-Nasdaq publicly listed Dutch company having its pri
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019 Important Notice and Disclaimer THIS PRESENTATION HAS BEEN PREPARED BY INFLARX n.v. ("INFLARX"), a US-Nasdaq publicly listed Dutch company having its principle place of business in germany. THIS PRESENTATION IS
Read more →IFRXInflaRx Full Year 2018 Financial & Operating Results $62.9 million ( 53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1 Start of three Phase II trials for IFX-1 in two serious inflammator
InflaRx Full Year 2018 Financial & Operating Results Jena, Germany, 28 March 2019 - InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the year en
Read more →IFRXInflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmu
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum Jena, Germany, February 27, 2019 InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the co
Read more →IFRXRichard Brudnick to Join InflaRx Board of Directors Jena, Germany
Richard Brudnick to Join InflaRx Board Germany, February 14, 2019 - InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that Mr. Richard Brudnick has been appointed, as inte
Read more →IFRXInflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatment Baseline ch
InflaRx Announces Presentation of New Clinical Lead Candidate IFX-1 in Hidradenitis Suppurativa Germany and NEW YORK Feb. 6, 2019 (Globe Newswire) - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory dis
Read more →IFRXInflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management Jason Marks appointed Chief Legal Officer / General Counsel Jordan Silverstein appointed Head of Corporate Strat
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management Germany and NEW YORK, Jan. 03, 2019 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory d
Read more →IFRXInflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis Jena, Germany
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis Germany, December 19, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by
Read more →IFRXInflaRx N.V. Amsterdam Condensed Consolidated Interim Financial Statements InflaRx N.V. and subsidiaries Unaudited condensed consolidated statements of comprehensive loss For the three months ended September 30, For the
Condensed Consolidated Interim Financial Statements InflaRx N.V. and subsidiaries consolidated statements of comprehensive loss For the three months ended September 30, For the nine months ended September 30, in thousand Note 2017 2018 2017 2018 Other income and exp
Read more →IFRXInflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results
Completion of patient recruitment in phase IIb trial in Hidradenitis Suppurativa First patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis Board of Directors appointment Jens Holstein, Chief Financial Officer of MorphoSys AG JENA, Germany, Nov. 21, 2018 (G
Read more →IFRXInflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa Trial Results Anticipated First Half 2019 Jena, Germany
InflaRx Completes Enrollment in Phase IIb with Lead Candidate IFX-1 in Hidradenitis Suppurativa Trial Results Anticipated First Half 2019 Jena, Germany, November 08, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat de
Read more →IFRXInflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing Jena, Germany
Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing Jena, Germany October 30, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the c
Read more →IFRXInflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors Jena, Germany
InflaRx N.V. Announces Appointment to Board of Directors Germany, September 21, 2018 - InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory diseases by targeting the complement system
Read more →IFRXInflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1
Live webcast on Friday, September 7, 2018, 7.45-9.30 am EDT (1.45-3.30 pm CET) JENA, Germany, Aug. 28, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening and devastating inflammatory disea
Read more →IFRXCONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of InflaRx N.V. (the Company ) to be held on
the convening notice for the extraordinary general meeting of shareholders of InflaRx N.V. (the "Company") to be held on September 21, 2018 at 10.00 a.m. (CEST) at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "EGM"). for the EGM
Read more →IFRXInflaRx N.V. Amsterdam Condensed Consolidated Interim Financial Statements InflaRx N.V. and subsidiaries Unaudited condensed consolidated statements of comprehensive loss For the three months ended June 30, For the six m
Condensed Consolidated Interim Financial Statements InflaRx N.V. and subsidiaries consolidated statements of comprehensive loss For the three months ended June 30, For the six months ended June 30, in thousand Note 2017 2018 2017 2018 Other income and expenses (net)
Read more →IFRXInflaRx N.V. Reports Second Quarter 2018 Financial & Operating Results
Received FDA clearance of IND for Phase II trial of IFX-1 in ANCA-associated vasculitis Established U.S. research facility to continue advancing complement-based research Completion of follow-on offering raising $62.9 million in primary proceeds Cash position approximately €15
Read more →IFRXInflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis Jena, Germany
InflaRx Receives IND Approval from the FDA Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis Jena, Germany, June 28, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases
Read more →IFRXInflaRx Opens New Research Facility in Ann Arbor R&D activities will focus on proprietary complement science Site will be overseen by InflaRx Chief Scientific Officer Jena, Germany, 5 June 2018 - InflaRx N.V. (Nasdaq: IF
InflaRx Opens New Research Facility in Ann R&D activities will focus on proprietary Site will be overseen by InflaRx Chief Jena, Germany, 5 June 2018 - InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threatening infla
Read more →IFRXInflaRx Opens New Research Facility in Ann Arbor
R&D activities will focus on proprietary complement science Site will be overseen by InflaRx Chief Scientific Officer JENA, Germany, June 05, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat life-threat
Read more →IFRXInflaRx N.V. Amsterdam Unaudited Condensed Consolidated Financial Statements InflaRx N.V. and subsidiaries Unaudited condensed consolidated statements of comprehensive loss for the three months ended March 31, in thousan
Unaudited Condensed Consolidated Financial Statements InflaRx N.V. and subsidiaries consolidated statements of comprehensive loss for the three months in thousand Note 2017 2018 Other income and expenses (net) 28 70 Research and development expenses (2,401 )
Read more →IFRXInflaRx N.V. Reports First Quarter 2018 Financial & Operating Results
Initiated international Phase IIb study of IFX-1 in Hidradenitis Suppurativa patients Completion of primary and secondary offering of US$117 million Cash position approximately US$137 million (€115 million) as of March 31, 2018 JENA, Germany, May 17, 2018 (GLOBE NEWSWIRE) -- I
Read more →IFRXInflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares
JENA, Germany, May 08, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today the closing o
Read more →IFRXInflaRx N.V. Announces Pricing of Primary and Secondary Offering of Common Shares
JENA, Germany, May 03, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today the pricing o
Read more →IFRXCONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of InflaRx N.V. (the Company ) to be held on
the convening notice for the annual general meeting of shareholders of InflaRx N.V. (the "Company") to be held on May 17, 2018 at 11.30 a.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands for the AGM is as follows: shall be vot
Read more →IFRXInflaRx N.V. Announces Proposed Primary and Secondary Offerings of Common Shares
JENA, Germany, May 02, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat inflammatory diseases by targeting the complement system, a key component of the innate immune system, announced today that the Comp
Read more →IFRXInflaRx Full Year 2017 Financial & Operating Results IFX-1 Positive Phase IIa data in Hidradenitis Suppurativa (HS) patients US$136 million Series D & Nasdaq IPO financings U.S. IND opened, international Phase IIb initia
Full Year 2017 Financial & Operating Results Phase IIa data in Hidradenitis Suppurativa (HS) patients US$136 million Series D & Nasdaq IPO financings U.S. IND opened, international Phase IIb initiated for IFX-1 in HS patients Strong cash position with approx. US$148 million (
Read more →IFRXInflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa Jena, Germany, March 8 , 2018 - InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new t
announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa Germany, March 8, 2018 - InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today announced enrollment
Read more →IFRXInflaRx announces appointment of Tony Gibney to InflaRx`s Board Jena, Germany
appointment of Tony Gibney Germany, February 6, 2018 - InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing new therapeutics in the terminal complement space, today announced the addition of Tony Gibney to its Board of Directors. Mr. Gibney is a highly experienced
Read more →IFRXInflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Jena, Germany
InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Germany, January 9, 2018 - InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in the terminal complement space, today anno
Read more →IFRXInflaRx GmbH Index to Unaudited Interim Condensed Consolidated Financial Statements Unaudited condensed consolidated statements of comprehensive loss 2 Condensed consolidated statements of financial position as of
Index to Unaudited Interim Condensed Consolidated Financial Statements Unaudited condensed consolidated statements of comprehensive loss 2 Condensed consolidated statements of financial position as of December 31, 2016 (audited) and September 30, 2017 (unaudited) 3 Unaudited co
Read more →IFRXInflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Nov. 08, 2017 (GLOBE NEWSWIRE) -- InflaRX NV (Nasdaq:IFRX), a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a, will visit the Nasdaq MarketSit
Read more →Competitive Position
How IFRX ranks across every disease it competes inCompetitive Position is a premium feature
See how IFRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial